{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:10:13Z","timestamp":1758874213660,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A\u00a0non-inferiority clinical study evaluated the efficacy and safety of abobotulinumtoxinA vs. incobotulinumtoxinA intradetrusor injections in women with overactive bladder and urge urinary incontinence. Also, the effect of local anesthesia on the pain level of the procedure was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients were randomized to receive 20\u00a0intradetrusor injections of either 300\u202fU abobotulinumtoxinA or 100\u202fU incobotulinumtoxinA. They were further randomized to receive either local anesthesia (40\u202fml 1% lidocaine solution) or placebo before botulinum toxin injection. Before the procedure and 4\u00a0months after the procedure each patient reported urinary incontinence episodes, frequency, nocturia, completed the Urogenital Distress Inventory (UDI-6) score, Incontinence Impact Questionnaire (IIQ-7), and Incontinence Quality of Life (I-QOL) questionnaire. Each patient completed a\u00a0patient satisfaction survey 4 months after the procedure. During the procedure, the patients graded the pain intensity of every injection on a\u00a0visual analog scale (VAS). The total score of each questionnaire was considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 54\u00a0patients with a\u00a0mean age of 66\u202f\u00b1\u200913\u00a0(SD) years completed the study. Total scores of UDI\u20116, IIQ\u20117, I\u2011QOL, patient satisfaction, urinary incontinence episodes, frequency, nocturia and VAS questionnaires did not show differences between the abobotulinumtoxinA (<jats:italic>n<\/jats:italic>\u202f=\u200926) or incobotulinumtoxinA (<jats:italic>n<\/jats:italic>\u202f=\u200928) group. Urinary retention requiring catheterization was noted in five patients. The VAS and patient satisfaction questionnaire values did not show significant differences between the group receiving bladder instillation with lidocaine solution (<jats:italic>n<\/jats:italic>\u202f=\u200928) or the group receiving placebo (<jats:italic>n<\/jats:italic>\u202f=\u200926).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In women with overactive bladder and urge urinary incontinence where conservative treatment failed, abobotulinumtoxinA vs. incobotulinumtoxinA intradetrusor injections showed comparable results regarding improved clinical outcome and patient satisfaction. Local anesthesia before the procedure did not reduce the pain level in comparison with the placebo.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02412-7","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:44:08Z","timestamp":1724420648000},"page":"470-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of intradetrusor abobotulinumtoxinA and incobotulinumtoxinA in women with overactive bladder  and the value of local anesthesia: a\u00a0randomized clinical study"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-3906","authenticated-orcid":false,"given":"Niko","family":"Kavcic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Avsenak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Zmazek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Serdinsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"But","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"2412_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams\u00a0P, Cardozo\u00a0L, Fall\u00a0M, Griffiths\u00a0D, Rosier\u00a0P, Ulmsten\u00a0U, Van Kerrebroeck\u00a0P, Victor\u00a0A, Wein\u00a0A. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61:37\u201349. https:\/\/doi.org\/10.1016\/S0090-4295(02)02243-4.","journal-title":"Urology"},{"key":"2412_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen\u00a0BT, de Ridder\u00a0D, Freeman\u00a0RM, Swift\u00a0SE, Berghmans\u00a0B, Lee\u00a0J, Monga\u00a0A, Petri\u00a0E, Rizk\u00a0DE, Sand\u00a0PK, et\u00a0al. An international urogynecological association (IUGA)\/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol\u00a0J. 2010;21:5\u201326. https:\/\/doi.org\/10.1007\/s00192-009-0976-9.","journal-title":"Int Urogynecol J"},{"key":"2412_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom\u00a0I, Abrams\u00a0P, Cardozo\u00a0L, Roberts\u00a0RG, Th\u00fcroff\u00a0J, Wein\u00a0AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A\u00a0population-based prevalence study. BJU Int. 2001;87:760\u20136. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02228.x.","journal-title":"BJU Int"},{"key":"2412_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"W Stewart","year":"2003","unstructured":"Stewart\u00a0W, Van Rooyen\u00a0J, Cundiff\u00a0G, Abrams\u00a0P, Herzog\u00a0A, Corey\u00a0R, Hunt\u00a0T, Wein\u00a0A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327\u201336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4.","journal-title":"World J Urol"},{"key":"2412_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clinthera.2013.04.013","volume":"35","author":"DL Patrick","year":"2013","unstructured":"Patrick\u00a0DL, Khalaf\u00a0KM, Dmochowski\u00a0R, Kowalski\u00a0JW, Globe\u00a0DR. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clin Ther. 2013;35:836\u201345. https:\/\/doi.org\/10.1016\/j.clinthera.2013.04.013.","journal-title":"Clin Ther"},{"key":"2412_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","volume":"75","author":"S Bartoli","year":"2010","unstructured":"Bartoli\u00a0S, Aguzzi\u00a0G, Tarricone\u00a0R. Impact on quality of life of urinary incontinence and overactive bladder: a\u00a0systematic literature review. Urology. 2010;75:491\u2013500. https:\/\/doi.org\/10.1016\/j.urology.2009.07.1325.","journal-title":"Urology"},{"key":"2412_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0302-2838(03)00054-X","volume":"43","author":"G Amarenco","year":"2003","unstructured":"Amarenco\u00a0G. European psychometric validation of the CONTILIFE\u00ae: a\u00a0quality of life questionnaire for urinary incontinence. Eur Urol. 2003;43:391\u2013404. https:\/\/doi.org\/10.1016\/S0302-2838(03)00054-X.","journal-title":"Eur Urol"},{"key":"2412_CR8","volume-title":"Uptodate","author":"SE Lukacz","year":"2024","unstructured":"Lukacz\u00a0SE. Urgency urinary incontinence\/overactive bladder (OAB) in females: treatment. In: Brubaker\u00a0L, editor. Uptodate Wolters Kluwer; 2024."},{"key":"2412_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000351037","volume":"91","author":"Y Cui","year":"2013","unstructured":"Cui\u00a0Y, Wang\u00a0L, Liu\u00a0L, Zeng\u00a0F, Niu\u00a0J, Qi\u00a0L, Chen\u00a0H. Botulinum toxin\u2011a injections for idiopathic overactive bladder: a\u00a0systematic review and meta-analysis. Urol Int. 2013;91:429\u201338. https:\/\/doi.org\/10.1159\/000351037.","journal-title":"Urol Int"},{"key":"2412_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/nau.23224","volume":"36","author":"A Coelho","year":"2017","unstructured":"Coelho\u00a0A, Antunes-Lopes\u00a0T, Gillespie\u00a0J, Cruz\u00a0F. Beta\u20113 Adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an Immunohistochemical study. Neurourol Urodyn. 2017;36:1972\u201380. https:\/\/doi.org\/10.1002\/nau.23224.","journal-title":"Neurourol Urodyn"},{"key":"2412_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel\u00a0MC, Cardozo\u00a0L, Chermansky\u00a0CJ, Cruz\u00a0F, Igawa\u00a0Y, Lee\u00a0K\u2011S, Sahai\u00a0A, Wein\u00a0AJ, Andersson\u00a0K\u2011E. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:554\u2013674. https:\/\/doi.org\/10.1124\/pharmrev.121.000523.","journal-title":"Pharmacol Rev"},{"key":"2412_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","volume":"67","author":"A Esquenazi","year":"2013","unstructured":"Esquenazi\u00a0A, Albanese\u00a0A, Chancellor\u00a0MB, Elovic\u00a0E, Segal\u00a0KR, Simpson\u00a0DM, Smith\u00a0CP, Ward\u00a0AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013;67:115\u201328. https:\/\/doi.org\/10.1016\/j.toxicon.2012.11.025.","journal-title":"Toxicon"},{"key":"2412_CR13","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S79193","author":"W Jost","year":"2015","unstructured":"Jost\u00a0W, Benecke\u00a0R, Hauschke\u00a0D, Jankovic\u00a0J, Ka\u0148ovsk\u00fd\u00a0P, Roggenk\u00e4mper\u00a0P, Simpson\u00a0DM, Comella\u00a0CL. Clinical and pharmacological properties of IncobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; https:\/\/doi.org\/10.2147\/DDDT.S79193.","journal-title":"Drug Des Devel Ther"},{"key":"2412_CR14","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.21.04227-2","author":"A Giannantoni","year":"2022","unstructured":"Giannantoni\u00a0A, Gubbiotti\u00a0M, Rubilotta\u00a0E, Balzarro\u00a0M, Antonelli\u00a0A, Bini\u00a0V. IncobotulinumtoxinA versus onabotulinumtoxinA Intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a\u00a0double-blind, randomized, non-inferiority trial. Minerva Urol Nephrol. 2022; https:\/\/doi.org\/10.23736\/S2724-6051.21.04227-2.","journal-title":"Minerva Urol Nephrol"},{"key":"2412_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera\u00a0A, Andersson\u00a0K\u2011E, Apostolidis\u00a0A, Chapple\u00a0C, Dasgupta\u00a0P, Giannantoni\u00a0A, Gravas\u00a0S, Madersbacher\u00a0S. Contemporary management of lower urinary tract disease with botulinum toxin a: a\u00a0systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.001.","journal-title":"Eur Urol"},{"key":"2412_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple\u00a0C, Sievert\u00a0K\u2011D, MacDiarmid\u00a0S, Khullar\u00a0V, Radziszewski\u00a0P, Nardo\u00a0C, Thompson\u00a0C, Zhou\u00a0J, Haag-Molkenteller\u00a0C. OnabotulinumtoxinA 100\u202fU significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a\u00a0randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249\u201356. https:\/\/doi.org\/10.1016\/j.eururo.2013.04.001.","journal-title":"Eur Urol"},{"key":"2412_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12955-021-01721-z","volume":"19","author":"K Skorupska","year":"2021","unstructured":"Skorupska\u00a0K, Grzybowska\u00a0ME, Kubik-Komar\u00a0A, Rechberger\u00a0T, Miotla\u00a0P. Identification of the urogenital distress inventory\u20116 and the incontinence impact questionnaire\u20117 cutoff scores in urinary incontinent women. Health Qual Life Outcomes. 2021;19:87. https:\/\/doi.org\/10.1186\/s12955-021-01721-z.","journal-title":"Health Qual Life Outcomes"},{"key":"2412_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF00451721","volume":"3","author":"SA Shumaker","year":"1994","unstructured":"Shumaker\u00a0SA, Wyman\u00a0JF, Uebersax\u00a0JS, McClish\u00a0D, Fantl\u00a0JA. Health-related quality of life measures for women with urinary incontinence: the incontinence impact questionnaire and the urogenital distress inventory. Qual Life Res. 1994;3:291\u2013306. https:\/\/doi.org\/10.1007\/BF00451721.","journal-title":"Qual Life Res"},{"key":"2412_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/nau.1930140206","volume":"14","author":"JS Uebersax","year":"1995","unstructured":"Uebersax\u00a0JS, Wyman\u00a0JF, Shumaker\u00a0SA, McClish\u00a0DK. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Neurourol Urodyn. 1995;14:131\u20139. https:\/\/doi.org\/10.1002\/nau.1930140206.","journal-title":"Neurourol Urodyn"},{"key":"2412_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0090-4295(98)00454-3","volume":"53","author":"DL Patrick","year":"1999","unstructured":"Patrick\u00a0DL, Martin\u00a0ML, Bushnell\u00a0DM, Yalcin\u00a0I, Wagner\u00a0TH, Buesching\u00a0DP. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology. 1999;53:71\u20136. https:\/\/doi.org\/10.1016\/S0090-4295(98)00454-3.","journal-title":"Urology"},{"key":"2412_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejogrb.2017.06.024","volume":"215","author":"KA Skorupska","year":"2017","unstructured":"Skorupska\u00a0KA, Miotla\u00a0P, Kubik-Komar\u00a0A, Skorupski\u00a0P, Rechberger\u00a0T. Development and validation of the Polish version of the urogenital distress inventory short form and the incontinence impact questionnaire short form. Eur J Obstet Gynecol Reprod Biol. 2017;215:171\u20134. https:\/\/doi.org\/10.1016\/j.ejogrb.2017.06.024.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2412_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/nau.23884","volume":"38","author":"D de S\u00e1 Dantas Bezerra","year":"2019","unstructured":"de S\u00e1 Dantas Bezerra\u00a0D, de Toledo\u00a0LGM, da Silva Carram\u00e3o\u00a0S, Silva Rodrigues\u00a0AF, Dmockowski\u00a0R, Auge\u00a0APF. A\u00a0prospective randomized clinical trial comparing two doses of abobotulinumtoxinA for idiopathic overactive bladder. Neurourol Urodyn. 2019;38:660\u20137. https:\/\/doi.org\/10.1002\/nau.23884.","journal-title":"Neurourol Urodyn"},{"key":"2412_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bju.12028","volume":"112","author":"P Ravindra","year":"2013","unstructured":"Ravindra\u00a0P, Jackson\u00a0BL, Parkinson\u00a0RJ. Botulinum toxin type\u00a0A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(\u00ae) ) or abobotulinumtoxinA (Dysport(\u00ae) ) make a\u00a0difference? BJU Int. 2013;112:94\u20139. https:\/\/doi.org\/10.1111\/bju.12028.","journal-title":"BJU Int"},{"issue":"5","key":"2412_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","volume":"61","author":"RP Manecksha","year":"2012","unstructured":"Manecksha\u00a0RP, Cullen\u00a0IM, Ahmad\u00a0S, McNeill\u00a0G, Flynn\u00a0R, McDermott\u00a0TE, Grainger\u00a0R, Thornhill\u00a0JA. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61(5):928\u201335. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.043.","journal-title":"Eur Urol"},{"key":"2412_CR25","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6182","author":"D Asafu-Adjei","year":"2019","unstructured":"Asafu-Adjei\u00a0D, Small\u00a0A, McWilliams\u00a0G, Galea\u00a0G, Chung\u00a0D, Pak\u00a0J. The Intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. Can Urol Assoc\u00a0J. 2019; https:\/\/doi.org\/10.5489\/cuaj.6182.","journal-title":"Can Urol Assoc J"},{"key":"2412_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.toxicon.2021.07.005","volume":"200","author":"A Grishin","year":"2021","unstructured":"Grishin\u00a0A, Spaska\u00a0A, Kayumova\u00a0L. Correction of overactive bladder with Botulinum toxin type\u00a0A (BTX-A). Toxicon. 2021;200:96\u2013101. https:\/\/doi.org\/10.1016\/j.toxicon.2021.07.005.","journal-title":"Toxicon"},{"key":"2412_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/toxins10120535","volume":"10","author":"M Field","year":"2018","unstructured":"Field\u00a0M, Splevins\u00a0A, Picaut\u00a0P, van der Schans\u00a0M, Langenberg\u00a0J, Noort\u00a0D, Foster\u00a0K. AbobotulinumtoxinA (Dysport\u00ae), onabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients. Toxins. 2018;10:535. https:\/\/doi.org\/10.3390\/toxins10120535.","journal-title":"Toxins"},{"key":"2412_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","volume":"47","author":"J Grosse","year":"2005","unstructured":"Grosse\u00a0J, Kramer\u00a0G, St\u00f6hrer\u00a0M. Success of repeat detrusor injections of botulinum\u00a0a\u00a0toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47:653\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2004.11.009.","journal-title":"Eur Urol"},{"key":"2412_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3978\/j.issn.2223-4683.2016.01.10","volume":"5","author":"F Weckx","year":"2016","unstructured":"Weckx\u00a0F, Tutolo\u00a0M, De Ridder\u00a0D, Van der Aa\u00a0F. The role of botulinum toxin a in treating neurogenic bladder. Transl Androl Urol. 2016;5:63\u201371. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2016.01.10.","journal-title":"Transl Androl Urol"},{"key":"2412_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/toxins8030065","volume":"8","author":"F Scaglione","year":"2016","unstructured":"Scaglione\u00a0F. Conversion ratio between botox\u00ae, dysport\u00ae, and xeomin\u00ae in clinical practice. Toxins. 2016;8:65. https:\/\/doi.org\/10.3390\/toxins8030065.","journal-title":"Toxins"},{"key":"2412_CR31","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/jcm12041462","volume":"12","author":"S Lange","year":"2023","unstructured":"Lange\u00a0S, Koch\u00a0M, Lange\u00a0R, Husslein\u00a0H, Umek\u00a0W, Bodner-Adler\u00a0B. Perioperative techniques for the use of botulinum toxin in overactive bladder: results of a\u00a0multinational online survey of urogynecologists in Germany, Austria, and Switzerland. J\u00a0Clin Med. 2023;12:1462. https:\/\/doi.org\/10.3390\/jcm12041462.","journal-title":"J Clin Med"},{"key":"2412_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","volume":"11","author":"S Bellows","year":"2019","unstructured":"Bellows\u00a0S, Jankovic\u00a0J. Immunogenicity associated with botulinum toxin treatment. Toxins. 2019;11:491. https:\/\/doi.org\/10.3390\/toxins11090491.","journal-title":"Toxins"},{"key":"2412_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/nau.22642","volume":"34","author":"DJ Osborn","year":"2015","unstructured":"Osborn\u00a0DJ, Kaufman\u00a0MR, Mock\u00a0S, Guan\u00a0MJ, Dmochowski\u00a0RR, Reynolds\u00a0WS. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34:675\u20138. https:\/\/doi.org\/10.1002\/nau.22642.","journal-title":"Neurourol Urodyn"},{"key":"2412_CR34","doi-asserted-by":"publisher","first-page":"101066","DOI":"10.1016\/j.cont.2023.101066","volume":"9","author":"R Mohamed-Ahmed","year":"2024","unstructured":"Mohamed-Ahmed\u00a0R, Tomlinson\u00a0C, Taithongchai\u00a0A, Rantell\u00a0A, Araklitis\u00a0G, Robinson\u00a0D, Cardozo\u00a0L. Long term safety outcomes and continuation rates of repeated Intravesical botulinum toxin a injections for detrusor overactivity: 16 year\u2019s experience of a\u00a0tertiary centre in the UK. Continence. 2024;9:101066. https:\/\/doi.org\/10.1016\/j.cont.2023.101066.","journal-title":"Continence"},{"key":"2412_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.juro.2006.10.050","volume":"177","author":"BL Cohen","year":"2007","unstructured":"Cohen\u00a0BL, Rivera\u00a0R, Barboglio\u00a0P, Gousse\u00a0A. Safety and tolerability of sedation-free flexible cystoscopy for Intradetrusor botulinum toxin\u2011a injection. J\u00a0Urol. 2007;177:1006\u201310. https:\/\/doi.org\/10.1016\/j.juro.2006.10.050. discussion 1010,.","journal-title":"J Urol"},{"key":"2412_CR36","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.5489\/cuaj.7886","volume":"17","author":"J Ross","year":"2023","unstructured":"Ross\u00a0J, Hickling\u00a0D, Maciejewski\u00a0C, Coriaty\u00a0R, Vigil\u00a0H. Intravesical botulinum toxin: practice patterns from a\u00a0survey of Canadian urologists. Can Urol Assoc\u00a0J. 2023;17:E15\u2013E22. https:\/\/doi.org\/10.5489\/cuaj.7886.","journal-title":"Can Urol Assoc J"},{"key":"2412_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/nau.22750","volume":"35","author":"AK Nambiar","year":"2016","unstructured":"Nambiar\u00a0AK, Younis\u00a0A, Khan\u00a0ZA, Hildrup\u00a0I, Emery\u00a0SJ, Lucas\u00a0MG. Alkalinized lidocaine versus lidocaine gel as local anesthesia prior to intra-vesical botulinum toxin (BoNTA) injections: a\u00a0prospective, single center, randomized, double-blind, parallel group trial of efficacy and morbidity. Neurourol Urodyn. 2016;35:522\u20137. https:\/\/doi.org\/10.1002\/nau.22750.","journal-title":"Neurourol Urodyn"},{"key":"2412_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.sc.3101593","volume":"42","author":"B Schurch","year":"2004","unstructured":"Schurch\u00a0B, Reitz\u00a0A, Tenti\u00a0G. Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum\u2011a toxin injections into the detrusor. Spinal Cord. 2004;42:338\u201341. https:\/\/doi.org\/10.1038\/sj.sc.3101593.","journal-title":"Spinal Cord"},{"key":"2412_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/AOG.0000000000000468","volume":"124","author":"M Kalder","year":"2014","unstructured":"Kalder\u00a0M, Pantazis\u00a0K, Dinas\u00a0K, Albert\u00a0U\u2011S, Heilmaier\u00a0C, Kostev\u00a0K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol Clin North Am. 2014;124:794\u2013800. https:\/\/doi.org\/10.1097\/AOG.0000000000000468.","journal-title":"Obstet Gynecol Clin North Am"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02412-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02412-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02412-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:33:10Z","timestamp":1755757990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02412-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":39,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2412"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02412-7","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.\u00a0Kavcic, A.\u00a0Avsenak, J.\u00a0Zmazek, T.\u00a0Serdinsek and I.\u00a0But declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board Statement: this study was conducted in accordance with the Declaration of Helsinki, and approved by The National Medical Ethics Committee of the Republic of Slovenia (approval number 0120-44\/2018\/5; date of approval 22\/02\/2018). The trial was registered as an internal research project at our institution: University Medical Centre Maribor (project number IRP-2018\/01-14). The trial was also retrospectively registered on clinicaltrials.gov (registration number NCT06250543). Informed consent statement: informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}